Verywell Health on MSN4d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionFact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
Hosted on MSN1d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to knowA nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
ScienceAlert on MSN9d
FDA-Approved Nasal Spray For Depression Is First Of Its KindA ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback